The index case had recurrent biliary colics without having cholangitis due to
Fasciola hepatica. Although hailing from an endemic area (Egypt) he has been living in non-endemic zone (Saudi Arabia) for the last 8 years now implying that even brief exposure to an endemic zone can lead to infestation of the parasite. Various cases of biliary fascioliasis described in the literature [
4], [
7] have demonstrated obstructive jaundice to be the commonest presentation, however, the index case had no jaundice or cholangitis during four years of his intermittent illness. It is possible that there was a low worm load in the biliary system of the index case which allowed free flow of bile. There has to be high degree of suspicion to diagnose biliary fascioliasis as a cause of recurrent biliary colics especially in non-endemic areas. Although painful cholestasis associated with eosionphilia should make high suspicion of parasitosis as a case of biliary obstruction, the index case had no eosinophilia. Eosionphilia is striking in the hepatic phase and may not be observed in the biliary phase of the life cycle of the parasite as in the index case. During the first 3–4 months of acute infection, immunologic techniques play an important role in the diagnosis of fascioliasis. An enzyme-linked immunosorbent assay (ELISA) has a sensitivity of 100% and a specificity of 97.8% [
2], [
4]. During the early larval stage of infection, eggs are not found in the stool. The diagnosis can be made by finding characteristic ova in feces, duodenal aspirates, or bile specimens in the biliary phase of the parasite. Eggs are non-embryonated, ovoid, and large (130–150 × 60–90 µm), with a small operculum. Eggs being released sporadically it may be necessary to examine number of concentrated stool specimens to reach the diagnosis. The stool analysis in the index case was negative for ova and parasites, possibly we didn’t repeat the analysis multiple times. We had low presumption of fascioliasis before ERCP and no serology was done in the index case. In the biliary phase of the parasite CT scan may demonstrate hypodense nodules or tortuous tracks resulting from migration of the parasite, in addition to dilatation of biliary radicals [
8]. Endoscopic ultrasound and ERCP may demonstrate irregular thickening of the common bile duct and ERCP having therapeutic potential has been preferred by most of the workers in the management of biliary fascioliasis [
3], [
4], [
7]. The radiological picture of fascioliasis may even mimic other biliary disorders. For example Mohammad et al. [
9] reported a 34-year-old male with obstructive jaundice having features of cholangiocarcinoma on magnetic resonance cholangiopancreatography (MRCP). Their patient proved to have fascioliasis on ERCP. The adult parasite mainly inhabits the biliary system and causes biliary complication but there are reports of pancreatitis caused by
Fasciola hepatica [
10], [
11]. Maryo et al. [
11] postulated that the eggs laid by the adult parasite cause obstruction at the papilla leading to pancreatitis and hence risk of pancreatitis is proportional to the worm load in a given case. Biliary phase of the parasite mimicking sphincter of Oddi dysfunction was reported by Keshishian et al. [
12]. Thus biliary phase of the parasite has a complex clinical spectrum. It may present as biliary colics, cholangitis or pancreatitis and requires ERCP for removal of the parasite. In contrast the hepatic phase usually presents as abdominal pain, fever and jaundice. The hepatic phase is treated with triclabendazole which can be given as a single oral dose of 10 mg/kg or, in cases of severe infection, in two doses (10 mg/kg) given 12 h apart. Tablet triclabendazole 250 mg (manufactured by Novartis) is related to the benzimidazole–2–carbamate anthelmintics and has been approved for human biliary fascioliasis. This drug is shown to penetrate liver flukes by transtegumentary absorption followed by inhibition of the parasite’s motility by causing the destruction of the microtubular structure, resulting in the death of the parasite [
13].